Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,830,028
  • Shares Outstanding, K 51,624
  • Annual Sales, $ 782,400 K
  • Annual Income, $ 62,700 K
  • 60-Month Beta 1.55
  • Price/Sales 3.59
  • Price/Cash Flow 15.23
  • Price/Book 2.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.82
  • Number of Estimates 2
  • High Estimate 1.95
  • Low Estimate 1.69
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +142.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.97 +4.58%
on 10/22/19
61.77 -12.01%
on 11/07/19
-0.56 (-1.02%)
since 10/18/19
3-Month
39.11 +38.97%
on 08/27/19
61.77 -12.01%
on 11/07/19
+10.70 (+24.51%)
since 08/16/19
52-Week
39.11 +38.97%
on 08/27/19
73.89 -26.44%
on 12/03/18
-16.92 (-23.74%)
since 11/16/18

Most Recent Stories

More News
Emergent BioSolutions to Host 2019 Analyst and Investor Day

Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event is designed for sellside research analysts...

EBS : 54.35 (-0.86%)
EBS or ILMN: Which Is the Better Value Stock Right Now?

EBS vs. ILMN: Which Stock Is the Better Value Option?

EBS : 54.35 (-0.86%)
ILMN : 306.67 (+0.22%)
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

SNY : 46.71 (+1.30%)
GSK : 44.33 (+0.54%)
EBS : 54.35 (-0.86%)
ANIK : 60.09 (+0.13%)
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

EBS : 54.35 (-0.86%)
Emergent Biosolutions: 3Q Earnings Snapshot

GAITHERSBURG, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Wednesday reported third-quarter net income of $43.2 million.

EBS : 54.35 (-0.86%)
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

Q3 2019 performance above guidance

EBS : 54.35 (-0.86%)
Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EBS : 54.35 (-0.86%)
Emergent Biosolu Shares Up 13.1% Since SmarTrend's Buy Recommendation (EBS)

SmarTrend identified an Uptrend for Emergent Biosolu (NYSE:EBS) on September 3rd, 2019 at $48.28. In approximately 2 months, Emergent Biosolu has returned 13.11% as of today's recent price of $54.61.

EBS : 54.35 (-0.86%)
Emergent BioSolutions to Host 2019 Analyst & Investor Day

Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which is designed for sellside research...

EBS : 54.35 (-0.86%)
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

SNY : 46.71 (+1.30%)
GSK : 44.33 (+0.54%)
EBS : 54.35 (-0.86%)
EXAS : 82.16 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade EBS with:

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

2nd Resistance Point 56.40
1st Resistance Point 55.37
Last Price 54.35
1st Support Level 53.36
2nd Support Level 52.38

See More

52-Week High 73.89
Fibonacci 61.8% 60.60
Fibonacci 50% 56.50
Last Price 54.35
Fibonacci 38.2% 52.40
52-Week Low 39.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar